AdoRx is focused on the discovery of adenosine receptor antagonists that have been designed to engage their targets in the presence of high adenosine levels in the tumour microenvironment.
AdoRx preclinical programs include antagonists of the Adenosine A2A receptor and dual blockade of the A2A/A2B receptors.